Can Novartis take on Boehringer and Glaxo with its new COPD combo?

The drug maker plans to launch Utibron Neohaler (indacaterol/glycopyrrolate) for chronic obstructive pulmonary disorder (COPD) by Q1 2016. It'll have to elbow its way into the field.

By Nicole Gray • Nov. 2, 2015

Merck lowers cost of Remicade in UK as biosimilars enter market

Earlier this year, the National Insitute of Health and Clinical Excellence (NICE) lowered approved biosimilar versions of Remicade (infliximab). 

By Nicole Gray • Oct. 29, 2015

Senate efforts to advance 21st Century Cures aims appear stymied

Since the 21st Century Cures Act was introduced in April 2014, the political climate has become much less pro-pharma.

By Nicole Gray • Oct. 29, 2015

FDA approves Amgen's first-in-class oncolytic viral therapy

Imlygic (talimogene laherparepvec) is an oncolytic immunotherapy that uses a genetically modified strain of the herpes virus. 

By Nicole Gray • Oct. 29, 2015

Despite concerns, Express Scripts sticks with AbbVie's hep C therapy

Last week, the FDA warned about increased risk of serious liver injury associated with the VieKira Pak therapy. 

By Nicole Gray • Oct. 29, 2015

FDA inspection calls Theranos 'nanotainers' uncleared devices, cites quality assurance problems

The agency conducted inspections at two CA-based Theranos facilities from August 25 to September 16. 

By Nicole Gray • Oct. 27, 2015

Alexion shocks with lower-than-expected price for just-approved orphan drug

Alexion's Strensiq is the first approved treatment for hypophosphatasia (HPP).

By Nicole Gray • Oct. 26, 2015

FDA cautiously recommends approval of AZ's gout drug

A panel of independent FDA advisers voted 10-4 in favor of approving lesinurad, but the vote on approving the drug's safety profile was less positive. 

By Nicole Gray • Oct. 25, 2015

San Diego-based compounder to offer $1 alternative to Turing's Daraprim

The market responds to Martin Shkreli and Turing Pharma's 5,000% price hike on the drug.

By Nicole Gray • Oct. 22, 2015

FDA approves a new pancreatic cancer drug, Merrimack's Onivyde

But it comes with a black box warning for "severe neutropenia and diarrhea."

By Nicole Gray • Oct. 22, 2015

FDA questions AstraZeneca about safety of phase 3 gout drug

The company has submittted a dossier for the candidate, lesinurad, to the FDA and is awaiting a panel recommendation. 

By Nicole Gray • Oct. 22, 2015

REPORT: American man in India illegally exported execution drugs to Nebraska, other states

Chris Harris set up an office in India from which he offered sodium thiopental to states, which wanted to stock execution drugs, according to an investigative report by BuzzFeed. The sales date back to 2010.

By Nicole Gray • Oct. 21, 2015

The Amarin effect? FDA removes warning letter aimed at Pacira from web site

This is the latest action resulting from pharma companies pushing back against what they see as FDA over-regulation and attempting to protect their First Amendment rights. 

By Nicole Gray • Oct. 21, 2015

23andMe relaunches expanded genetic tests after 2-year, FDA-mandated hiatus

The firm will begin presenting users with health data once again—and this time, with regulators' approval and at a far higher price.

By Sy Mukherjee • Oct. 21, 2015

A Boehringer SVP and BioSig's CEO dish on the 'heart' of innovation

BioPharma Dive spoke with Dr. Sabine Luik, Senior Vice President of Medicine & Regulatory Affairs at Boehringer Ingelheim and Greg Cash, CEO of BioSig Technologies, about different strategies for reducing the risk of stroke in patients with atrial fibrillation—and what makes their products innovative.

By Nicole Gray • Oct. 20, 2015

A bipartisan bashing: Rubio slams drug prices, pharma's 'pure profiteering'

The GOP presidential hopeful from Florida joins Democrats Hillary Clinton and Bernie Sanders in criticizing what he sees as the industry's excesses and calls for pay-for-performance. 

By Sy Mukherjee • Oct. 20, 2015

FDA tells Theranos to stop using its tech except for approved herpes test

The agency's request comes on the heels of a bombshell report alleging that the company has been misrepresenting the use and efficacy of its pioneering blood test technology, which uses tiny vials of blood.

By Nicole Gray • Oct. 19, 2015

Shire's case for a Baxalta takeover dims as FDA spurns lead eye drug

Lifitegrast, which is intended to treat chronic dry eye disease, has long been considered one of the strongest candidates in Shire's pipeline. The company says it will refile the therapy in Q1 2016.

By Nicole Gray • Oct. 19, 2015

FDA approves first-ever Pradaxa 'antidote,' BI's Praxbind

Praxbind (idarucizumab), which is designed to reverse the effects of the anticoagulant Pradaxa (dabigatran), is a fully humanized antibody fragment.

By Nicole Gray • Oct. 19, 2015

Breast Cancer Awareness Month: A look at recent innovations in breast cancer

This month marks the 30th year of Breast Cancer Awareness Month (BCAM). In recognition of the milestone, here is a brief look at recent innovations in diagnosis, surgery, and medical treatment for the disease.  

By Nicole Gray • Oct. 16, 2015

FDA schedules separate meetings to review BioMarin, Sarepta Duchenne drugs

The agency has raised some eyebrows by scheduling panel meetings two months apart for drugs designed to address the same rare disease. 

By Nicole Gray • Oct. 15, 2015

23andMe nabs $115M in new financing and a $1.1B valuation

The consumer genetic testing firm comes surging back with a strong Series E.

By Nicole Gray • Oct. 15, 2015

Why Bernie Sanders' opposition to Califf's FDA nomination is misguided

Presidential candidate Bernie Sanders said he was proud to call pharma his number one enemy during the Democratic presidential debate last night. But that antipathy may have led him to a misleading argument against Dr. Califf.

By Nicole Gray • Oct. 14, 2015

FDA delays decision on Collegium's painkiller

Last month, an FDA panel recommended the long-acting opioid painkiller, Xtampza, for approval with on a 23-0 vote.

By Nicole Gray • Oct. 13, 2015

Good news on the horizon for Indian pharma as FDA ramps up approvals

Analysts expect the period between March 2015 and March 2016 to be much better in terms of earnings than the comparable period last year, thanks in large part to more FDA drug approvals. 

By Nicole Gray • Oct. 13, 2015